NPPA 30% Trade Margin Cap on Cancer Drugs

NPPA Trade Margin Cap on Cancer Drugs: The 30% Order, the MRP Formula and the Supreme Court Petitions

The National Pharmaceutical Pricing Authority (NPPA) has imposed a 30% trade margin cap on 137 non-scheduled anti-cancer drugs, effective 9 November 2026. Under the cap, the maximum retail price (MRP) of any medicine containing these drugs must leave no more than 30% of that price for the trade channel. NPPA notified the order on 17 October 2026, while two public interest litigation petitions on medicine pricing were being heard by the Supreme Court.

The Supreme Court has since reserved its judgment, after questioning why the Government's intervention stops at cancer drugs.

1. How Drug Prices Are Regulated in India: The DPCO Baseline

Medicine prices in India are regulated under the Drugs (Prices Control) Order, 2013 (DPCO), issued under Section 3 of the Essential Commodities Act, 1955. The NPPA administers the DPCO and the framework treats two categories of medicines very differently:

Two further provisions matter here:

• Paragraph 19 allows the Government, in extraordinary circumstances and in public interest, to fix the ceiling or retail price of any drug, scheduled or not. Every trade margin intervention so far has relied on this power.
• Paragraph 32 exempts certain new and patented drugs from price fixing, but only where an exemption has actually been granted. The 2026 order notes this and extends the cap to patented drugs.

The gap in this framework is simple. For non-scheduled medicines, nothing limits the difference between the price at which the manufacturer sells to the trade and the MRP printed on the pack. That difference is the trade margin.

2. The Supreme Court Petitions on Medicine Pricing

Two public interest litigation petitions are being heard together by a Bench of Justice Vikram Nath and Justice Sandeep Mehta.

Reliefs sought

As reported, the petitions together seek mandatory prescription of generic medicines (with disciplinary action against doctors who do not prescribe them), price regulation at the launch stage for non-scheduled medicines, statutory caps on the MRP and margins of medical devices, and strict enforcement of the DPCO across the supply chain.

Issues raised in the hearings

• Price gaps. Besides the cancer drug example noted below, the Court cited a medicine with a Rs 15 retailer price and a Rs 250 MRP, and a cardiac stent priced at Rs 5,000 to retailers and Rs 25,000 at MRP.
• Hospital pharmacies. Dr. Kulshresthra argued that retail chemists often give discounts, while corporate hospitals charge captive patients the full MRP. The Court observed that where such bills are reimbursed under government schemes, taxpayers bear the inflated cost.
• Antibiotics. The petitioner linked high antibiotic margins to antimicrobial resistance, citing an antibiotic with a printed price of Rs 4,196 available for Rs 980.

How the hearings unfolded

3. The NPPA Trade Margin Order of 17 October 2026

The order, S.O. 5690(E), invokes Paragraph 19 of the DPCO and, through Trade Margin Rationalisation (TMR), caps the trade margin at 30% for 137 non-scheduled anti-cancer drugs recommended by an Expert Committee of the Directorate General of Health Services. The list will be updated periodically. The order cites the catastrophic cost of cancer treatment and the wide gap between MRPs and actual transaction prices. The Centre's affidavit put average mark-ups on these drugs at about 170%, with some reaching 700%.

What the order covers

• All non-scheduled formulations containing any of the 137 drugs, whether alone or in combination, in any strength, dosage form or route of administration.
• Patented drugs, unless exempted under Paragraph 32.
• Formulations used for non-cancer purposes as well. The price applies whatever the therapeutic use.
• The list includes targeted therapies, immunotherapies and supportive-care drugs.

Key obligations on manufacturers

Obligations on hospitals, retailers and regulators

• Retailers, dealers, hospitals and institutions must display the manufacturer's price list prominently on their premises.
• Hospitals and medical institutions must monitor the MRPs of covered drugs, display the revised prices prominently on their websites and report violations to NPPA.
• State Drug Controllers will monitor compliance by manufacturers, dealers and hospitals.

Other important provisions

• Products already priced below the computed MRP must keep their existing MRP. The formula sets a ceiling and does not permit increases.
• Annual increases under Paragraph 20 remain available, but only while the 30% margin cap continues to be met.
• Earlier ceiling or retail price orders for these drugs under Paragraphs 4, 5 and 15 stand superseded.

Consequences of non-compliance

Failure to submit the revised price information is treated as failure to reduce the MRP. NPPA will recover the overcharged amount with interest under the DPCO read with the Essential Commodities Act, 1955. The overcharged amount is the MRP actually charged (excluding GST) minus the MRP permitted by the formula (excluding GST).

4. How the 30% Trade Margin Formula Works

In simple terms, the new MRP before GST can be no more than the manufacturer's selling price divided by 0.7. Table A of the order states it as follows:

MRP = PTS or PTD x [1 + TM/(100 - TM)] + Applicable GST

Here, PTS/PTD is the price to stockist or price to distributor, which is the manufacturer's price at the first point of sale. TM is the trade margin, which cannot exceed 30.

Step by step

1. Work out the PTS/PTD. It is the manufacturer's net sales realisation for the product in March 2026, divided by the quantity sold that month. In effect, this is the average net price actually received.
   • If there were no sales in March 2026, the average for April 2025 to March 2026 is used.
   • For a product launched after 31 March 2026, the current PTS/PTD is used.
   • All categories of sales count, except government sales.
   • Free supplies under a manufacturer's Patient Assistance Programme may be excluded. The manufacturer must give undertakings to NPPA and keep records of each patient's identity, residence, diagnosis and prescribed dose.
   • Where the manufacturer supplies a hospital directly, the hospital is treated as the distributor and the invoice price to the hospital is used.
2. Apply the multiplier. With TM at 30, the bracket becomes 1 + 30/70, which is about 1.4286.
3. Add GST, but only GST actually paid or payable to the Government.

The order's own illustration

Why it is "30% of MRP"

The Rs 30 margin in the illustration is 30% of the Rs 100 MRP. Measured against the Rs 70 selling price, the same Rs 30 is about 43%. So the cap is calculated on the MRP, not as a mark-up on the selling price.

The base also matters. The 16% margin for scheduled medicines is added to the price to retailer. The 30% here starts from the price to stockist. It therefore covers the whole chain after the manufacturer: stockist, wholesaler, retailer and, for direct supplies, the hospital.

Why March 2026

Fixing the base month before the policy was discussed in court prevents manufacturers from raising their selling prices to protect the final MRP.

5. Key Issues and Open Questions in the NPPA Order

• Use beyond cancer. The cap applies even where a listed drug is used for another condition. Some listed molecules have major non-oncology uses. Tocilizumab is used in rheumatoid arthritis, ofatumumab in multiple sclerosis and nintedanib in lung fibrosis. Products sold mainly for those uses are still covered.
• How the selling price is worked out. The new MRP is based on the average price the manufacturer actually received in March 2026, which the order calls "net sales realisation". The order does not say whether trade discounts, free units supplied with orders, or later credit notes must be subtracted. Each of these lowers the price actually received, and therefore the permitted MRP. Companies that treat them differently could arrive at different MRPs.
• One margin for every type of product. The trade gets the same 30% whether a product is an ordinary tablet or a biologic that must be kept refrigerated through transport and storage. For products that are costly to handle or slow to sell, distributors and retailers may find 30% too thin to cover their costs. The Centre raised this concern before the Supreme Court when opposing a uniform cap.
• Patient Assistance Programme records. To exclude free supplies, manufacturers must collect patients' identity documents, residence details and diagnoses. This is sensitive personal data and must be handled in line with data protection law.

6. Impact on Pharma Companies, Hospitals and Distributors

The order moves value from the trade channel to patients and payers, while leaving manufacturers' own selling prices largely untouched. The Government expects MRP reductions of up to 70% and patient savings of about Rs 2,500 crore a year. The pressure falls hardest where the gap between selling price and MRP has been widest: hospital pharmacies and trade-driven brands. The Centre has cautioned that over-regulation could affect the availability of some medicines in remote areas.

7. What to Watch: The Supreme Court Judgment

Judgment is reserved and the date of pronouncement is not known. The Bench has questioned why margin control stops at cancer drugs and has raised the 16% retailer margin as a possible benchmark, while the Centre favours a category-by-category approach. Businesses in the pharmaceutical, hospital and medical device sectors should plan for the possibility that margin caps are extended beyond oncology.

Frequently Asked Questions

What is the NPPA trade margin cap on cancer drugs?

It is a limit set by NPPA on the margin the trade channel can earn on 137 non-scheduled anti-cancer drugs. The trade margin cannot exceed 30% of the MRP.

When does the 30% trade margin cap take effect?

Revised prices take effect on 9 November 2026. NPPA notified the order on 17 October 2026.

How is the new MRP calculated?

The MRP before GST is the price to stockist or distributor (PTS/PTD) multiplied by 1 + 30/70. For example, a PTS of Rs 70 gives a maximum MRP of Rs 100 plus GST.

Does the cap apply to patented drugs?

Yes. Patented drugs are covered unless they have been exempted under Paragraph 32 of the DPCO.

What is the status of the Supreme Court petitions?

The Supreme Court reserved its judgment on 27 October 2026. No binding directions have been issued so far.